| abstract |
Provided are novel LRRK2 kinase inhibitors and methods of treating disease states using these inhibitors. Examples of LRRK2 kinase inhibitors are compounds of the formula: n nor derivatives thereof. An example is 1-(piperidin-1-yl)-2-((3-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)thio)butan-1-one. Particular uses include treating neurodegenerative diseases, cancer, autoimmune diseases and leprosy. |